With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Todays Updates

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Episode 155: Understanding Variability in Infantile Spasms Care Marco Meglio, Christina Briscoe, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Christina Briscoe, MD. [LISTEN TIME: 24 minutes]

Real-World Meta-Analysis Confirms Efficacy and Safety of CGRP Treatment Galcanezumab in Migraine Isabella Ciccone, MPH

Over the first 3 months of treatment, over 60% of patients with migraine treated with galcanezumab attained at least a 50% reduction in monthly migraine or headache days.

NeurologyLive® Friday 5 — November 28, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 28, 2025.

Sparsentan's Effect on Urinary Biomarkers in IgAN, With Chee Kay Cheung, MBChB, PhD Chee Kay Cheung, MBChB, PhD

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

ACR Convergence 2025 Recap: Late-Breaking Trials to Know

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Latest News

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

News All Time

First Patient Dosed in Phase 2 Extension Study of Sabirnetug in Early Alzheimer Disease Louie Pasculli

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy Isabella Ciccone, MPH

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows Louie Pasculli

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

NeurologyLive® Brain Games: November 16, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

Elena Grebenciucova, MD, on Evolving Standards in NMOSD Diagnosis and Management Elena Grebenciucova, MD, Marco Meglio

The assistant professor of neurology at Northwestern University explained key diagnostic, therapeutic, and management considerations for clinicians caring for patients with NMOSD across diverse and evolving clinical scenarios.

This Week on NeurologyLive® — November 17, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Multidisciplinary Care Paths That Improve Neurosarcoidosis Management Spencer Hutto, MD, Marco Meglio

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

Recommended News For You

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers

Stem Cell Selection Unneeded for SSc Transplant Therapy?

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis

Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state

Recommended Articles For You

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment 

Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential 

Understanding Iron Saturation Levels in Your Blood  

The Ultimate Guide to Understanding Abiraterone and its Uses in Cancer Treatment  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Papillary thyroid cancer: New markers offer hope for tailored treatment

2.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

3.

Modified personalized cancer vaccine generates powerful immune response

4.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

5.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

1.

Precision Oncology: Tailoring Cancer Treatment for the Individual

2.

Breast Cancer Secrets: AI-Powered Precision Medicine

3.

Improving TIVAP Use: Review of Standardization and Optimization Practices

4.

Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review

5.

Case Study: Personalized Medicine Based on Genetic Profiling in Oncology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

2.

Oropharyngeal Cancer in Relation to HPV Status

3.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

4.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

5.

Understanding the causes of anemia in adults beyond nutritional deficiencies

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot